Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab

@inproceedings{Tarhini2014ImmuneMO,
  title={Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab},
  author={Ahmad A Tarhini and Howard Edington and Lisa H Butterfield and Yue Lin and Yongli Shuai and Hussein Tawbi and Cindy Sander and Yan Yin and Matthew Peter Holtzman and Jonas T. Johnson and Uma Maheswar Rao and John Munn Kirkwood},
  booktitle={PloS one},
  year={2014}
}
We evaluated neoadjuvant ipilimumab in patients with surgically operable regionally advanced melanoma in order to define markers of activity in the blood and tumor as assessed at baseline (before ipilimumab) and early on-treatment. Patients were treated with ipilimumab (10 mg/kg intravenously every 3 weeks ×2 doses) bracketing surgery. Tumor and blood biospecimens were obtained at baseline and at surgery. Flow cytometry and immunohistochemistry for select biomarkers were performed. Thirty five… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 92 CITATIONS, ESTIMATED 43% COVERAGE

Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab

  • Journal of Translational Medicine
  • 2017
VIEW 6 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2016
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2014
2019

CITATION STATISTICS

  • 11 Highly Influenced Citations

  • Averaged 14 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL